Soo Yeon Cheong

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Annals of the Rheumatic Diseases · 2015 · 229 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Phase <scp>III</scp> Randomized Study of <scp>SB</scp>5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

Michael E. Weinblatt, Asta Baranauskaitė, Jaroslaw Niebrzydowski et al. · Arthritis & Rheumatology · 2017 · 133 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials

Jonathan I. Silverberg, Andreas Wollenberg, Adam Reich et al. · The Lancet · 2024 · 125 citations

Medicine, Dermatology, Pharmacotherapy +14

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Annals of the Rheumatic Diseases · 2017 · 110 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Variation in folate pathway genes contributes to risk of congenital heart defects among individuals with Down syndrome

Adam E. Locke, Kenneth J. Dooley, Stuart W. Tinker et al. · Genetic Epidemiology · 2010 · 85 citations

Medicine, Cardiology, Genetics +17